

**Publikace in extenso:**

**Články v časopisech s IF (IF 473)**

- 1 Marchesi F, Salmanton-García J, Emarah Z, Piukovics K, Nucci M, López-García A, Ráčil Z, Farina F, Popova M, Zompi S, Audisio E, Ledoux MP, Verga L, Weinbergerová B, Szotkovski T, Da Silva MG, Fracchiolla N, De Jonge N, Collins G, Marchetti M, Magliano G, García-Vidal C, Biernat MM, Van Doesum J, Machado M, Demirkan F, Al-Khabori M, Žák P, Víšek B, Stoma I, Méndez GA, Maertens J, Khanna N, Espigado I, Dragonetti G, Fianchi L, Del Principe MI, Cabirta A, Ormazabal-Vélez I, Jaksic O, Buquicchio C, Bonuomo V, Batinić J, Omrani AS, Lamure S, Finizio O, Fernández N, Falces-Romero I, Blennow O, Bergantim R, Ali N, Win S, Van Praet J, Tisi MC, Shirinova A, Schönlein M, Prattes J, Piedimonte M, Petzer V, Navrátil M, Kulasekararaj A, Jindra P, Sramek J, Glenthøj A, Fazzi R, De Ramón-Sánchez C, Cattaneo C, Calbacho M, Bahr NC, El-Ashwah S, Cordoba R, Hanakova M, Zambrotta G, Sciumè M, Booth S, Rodrigues RN, Sacchi MV, García-Poutón N, Martín-González JA, Khostelidi S, Gräfe S, Rahimli L, Ammatuna E, Busca A, Corradini P, Hoenigl M, Klimko N, Koehler P, Pagliuca A, Passamonti F, Cornely OA, Pagano L. COVID-19 in adult acute myeloid leukemia patients: a long-term followup study from the European Hematology Association survey (EPICOVIDEHA). *Haematologica*. 2023 Jan 1;108(1):22-33
- 2 Dimopoulos MA, Moreau P, Augustson B, Castro N, Pika T, Delimpasi S, De la Rubia J, Maiolino A, Reiman T, Martinez-Lopez J, Martin T, Mikhael J, Yong K, Risse ML, Asset G, Marion S, Hajek R. Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis. *Am J Hematol*. 2023 Jan;98(1):E15-E19.
- 3 Haertle L, Barrio S, Munawar U, Han S, Zhou X, Simicek M, Vogt C, Truger M, Fernandez RA, Steinhardt M, Weingart J, Snaurova R, Nerreter S, Teufel E, Garitano-Trojaola A, Da Viá M, Ruiz-Heredia Y, Rosenwald A, Bolli N, Hajek R, Raab P, Raab MS, Weinhold N, Haferlach C, Haaf T, Martinez-Lopez J, Einsele H, Rasche L, Kortüm KM. Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma. *Clin Cancer Res*. 2023 Jan 4;29(1):279-288
- 4 Palladini G, Schönland S, Merlini G, Milani P, Jaccard A, Bridoux F, Dimopoulos MA, Ravichandran S, Hegenbart U, Roeloffzen W, Cibeira MT, Agis H, Minnema MC, Bergantim R, Hájek R, João C, Leonidakis A, Cheliotis G, Sonneveld P, Kastiris E, Wechalekar A. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018. *Blood Cancer J*. 2023 Jan 25;13(1):19.
- 5 Jelinek T, Bezdekova R, Zihala D, Sevcikova T, Anilkumar Sithara A, Pospisilova L, Sevcikova S, Polackova P, Stork M, Knechtova Z, Venglar O, Kapustova V, Popkova T, Muronova L, Chyra Z, Hrdinka M, Simicek M, Garcés JJ, Puig N, Cedena MT, Jurczyszyn A, Castillo JJ, Penka M, Radocha J, Mateos MV, San-Miguel JF, Paiva B, Pour L, Rihova L, Hajek R. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma. *J Clin Oncol*. 2022 Oct 31;JCO2201226.
- 6 Piotr Celichowski, Marcello Turi, Sandra Charvátová, Dhvani Radhakrishnan, Neda Feizi, Zuzana Chyra, Michal Šimíček, Tomáš Jelínek, Juli Rodriguez Bago, Roman Hájek, Matouš Hrdinka. Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility. *J Transl Med*. 2023 Mar 15;21(1):197.
- 7 Sandra Charvátová, Benjamin Motais, Justyna Czapla, Tomasz Cichoń, Ryszard Smolarczyk, Zuzana Walek, Sebastian Giebel, Roman Hájek, Juli R Bagó. Novel Local "Off-the-Shelf" Immunotherapy for the Treatment of Myeloma Bone Disease. *Cells*. 2023 Jan 30;12(3):448
- 8 Daisuke Ogiya, Zuzana Chyra, Sigita J Verselis, Morgan O'Keefe, Jacquelyn Cobb, Ivane Abiatar, Srikanth Talluri, Anjana Anilkumar Sithara, Teru Hideshima, Michael P Chu, Roman Hájek, David M Dorfman, Linda M Pilarski, Kenneth C Anderson, Sophia Adamia. Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics. *Blood Cancer J*. 2023 Feb 3;13(1):23
- 9 Maisnar V, Pour L, Spicka I, Jelinek T, Minarik J, Jungova A et al. Patient Characteristics, Treatment Patterns and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data. *Clin Lymphoma Myeloma Leuk*. 2023 Feb;23(2):145-153.
- 10 Thompson MA, Boccadoro M, Leleu X, Vela-Ojeda J, van Rhee F, Weisel KC, Rifkin RM, Usmani SZ, Hájek R, Cook G, Abonour R, Armour M, Morgan KE, Yeh SP, Costello CL, Berdeja JG, Davies FE, Zonder JA, Lee HC, Omel J, Spencer A, Terpos E, Hungria VTM, Puig N, Fu C, Ferrari RH, Ren K, Stull DM, Chari A. Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients. *Clin Lymphoma Myeloma Leuk*. 2023 Mar;23(3):e171-e181

- 11 Cowan A, Ferrari F, Freeman SS, Redd R, El-Khoury H, Perry J, Patel V, Kaur P, Barr H, Lee DJ, Lightbody E, Downey K, Argyelan D, Theodorakakou F, Fotiou D, Liacos CI, Kanellias N, Chavda SJ, Ainley L, Sandecká V, Pospíšilová L, Minarik J, Jungova A, Radocha J, Spicka I, Nadeem O, Yong K, Hájek R, Kastritis E, Marinac CR, Dimopoulos MA, Get G, Trippa L, Ghobrial IM. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study. *Lancet Haematol.* 2023 Mar;10(3):e203-e212.
- 12 Dudová L, Hradská K, Popková T, Skořupová M, Hájek R. The Benefit of Telemonitoring in the Prevention of Septic Shock in a Patient with Aggressive Non-Hodgkin's Lymphoma. *Case Rep Oncol.* 2023 Mar 7;16(1):143-150.
- 13 Turi M, Anilkumar Sithara A, Hofmanová L, Žihala D, Radhakrishnan D, Vdovin A, Knápková S, Ševčíková T, Chyra Z, Jelínek T, Šimíček M, Gullà A, Anderson KC, Hájek R, Hrdinka M. Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling. *Int J Mol Sci.* 2023 Mar 15;24(6):5623.
- 14 Haertle L, Buenache N, Cuesta Hernández HN, Simicek M, Snaurova R, Rapado I, Martinez N, López-Muñoz N, Sánchez-Pina JM, Munawar U, Han S, Ruiz-Heredia Y, Colmenares R, Gallardo M, Sanchez-Beato M, Piris MA, Samur MK, Munshi NC, Ayala R, Kortüm KM, Barrio S, Martínez-López J. Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma. *Cancers (Basel).* 2023 Jan 15;15(2):532.
- 15 Dogliotti I, Jiménez C, Varettoni M, Talaulikar D, Bagratuni T, Ferrante M, Pérez J, Drandi D, Puig N, Gilestro M, García-Álvarez M, Owen R, Jurczak W, Tedeschi A, Leblond V, Kastritis E, Kersten MJ, D'Sa S, Kaščák M, Willenbacher W, Roccaro AM, Poulain S, Morel P, Kyriakou C, Fend F, Vos JMI, Dimopoulos MA, Buske C, Ferrero S, García-Sanz R. Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's Macroglobulinemia. *Leukemia.* 2023 Feb;37(2):388-395.
- 16 Ferrer-Curriu G, Soler-Botija C, Charvatova S, Motais B, Roura S, Galvez-Monton C, Monguió-Tortajada M, Iborra-Egea O, Emdin M, Lupón J, Aimo A, Bagó JR, Bayés-Genís A. Preclinical scenario of targeting myocardial fibrosis with chimeric antigen receptor (CAR) immunotherapy. *Biomed Pharmacother.* 2023 Feb;158:114061.
- 17 Šimkovič M, Turcsányi P, Špaček M, Mihályová J, Ryznerová P, Maco M, Vodárek P, Écsiová D, Poul H, Móciková H, Zuchnická J, Panovská A, Leka M, Oršulová M, Prchlíková A, Stejskal L, Mašlejová S, Brychtová Y, Bezděková L, Papajík T, Lysák D, Trněný M, Smolej L, Doubek M. COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group. *Ann Hematol.* 2023 Apr;102(4):811-817.
- 18 Buske C, Dimopoulos MA, Grunenberga A, Kastritis E, Tomowiak C, Mahé B, Troussard X, Hajek R, Viardot A, Tournilhac O, Aurran T, Lepretre S, Zerazhi H, Hivert B, Leblond V, de Guibert S, Brandefors L, Garcia-Sanz R, Gomes da Silva M, Kimby E, Schmelzle B, Kaszynski D, Dreyhaupt J, Muche R, Morel P. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia. *J Clin Oncol.* 2023 May 10;41(14):2607-2616
- 19 Martin T, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Macé S, Risse ML, Moreau P. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. *Blood Cancer J.* 2023 May 9;13(1):72.
- 20 Sonneveld P, Richardson PG, Ludwig H, Dimopoulos MA, Schjesvold FH, Hájek R, Abdulhaq H, Thuresson M, Norin S, Bakker NA, Mateos MV. Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies. *Clin Lymphoma Myeloma Leuk.* 2023 May 6;S2152-2650(23)00144-1
- 21 Burgos L, Tamariz-Amador LE, Puig N, Cedena MT, Guerrero C, Jelínek T, Johnson S, Milani P, Cordon L, Perez JJ, Lasa M, Termini R, Oriol A, Hernandez MT, Palomera L, Martinez-Martinez R, de la Rubia J, de Arriba F, Rios R, Gonzalez ME, Gironella M, Cabañas V, Casanova M, Krsnik I, Perez-Montaña A, González-Calle V, Rodriguez-Otero P, Maisnar V, Hajek R, Van Rhee F, Jimenez-Zepeda V, Palladini G, Merlini G, Orfao A, de la Cruz J, Martinez-Lopez J, Lahuerta JJ, Rosiñol L, Blade J, Mateos MV, San-Miguel JF, Paiva B; PETHEMA/GEM Cooperative Group. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies. *J Clin Oncol.* 2023 Jun 1;41(16):3019-3031.
- 22 Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, Michel Delforge, Gordon Cook, Francesca Gay, Niels W C J van de Donk, Ioannis Ntanasis-Stathopoulos, Annette Juul Vangsted, Christoph Driessen, Fredrik Schjesvold, Claudio Cerchione, Sonja Zweegman, Roman Hajek, Philippe Moreau, Hermann Einsele, Jesus San-Miguel, Mario Boccadoro, Meletios A Dimopoulos, Pieter Sonneveld, Heinz Ludwig. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN). *Leukemia.* 2023 Jun;37(6):1175-1185

- 23 Ludwig H, Terpos E, van de Donk N, Mateos MV, Moreau P, Dimopoulos MA, Delforge M, Rodriguez-Otero P, San-Miguel J, Yong K, Gay F, Einsele H, Mina R, Caers J, Driessen C, Musto P, Zweegman S, Engelhardt M, Cook G, Weisel K, Broijl A, Beksac M, Bila J, Schjesvold F, Cavo M, Hajek R, Touzeau C, Boccadoro M, Sonneveld P. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. *Lancet Oncol.* 2023 Jun;24(6):e255-e269.
- 24 Stork M, Spicka I, Radocha J, Minarik J, Jelinek T, Jungova A, Pavlicek P, Pospisilova L, Sedlak F, Straub J, Pika T, Knechtova Z, Fidirichova A, Boichuk I, Sevcikova S, Maisnar V, Hajek R, Pour L. Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysis. *Ann Hematol.* 2023 Jun;102(6):1501-1511
- 25 Špaček M, Smolej L, Šimkovič M, Nekvindová L, Křístková Z, Brychtová Y, Panovská A, Mašlejová S, Bezděková L, ěcsiová D, Vodárek P, Zuchnická J, Mihályová J, Urbanová R, Turcsányi P, Lysák D, Novák J, Brejcha M, Líkařová T, Vodička P, Baranová J, Trněný M, Doubek M; Czech CLL Study Group. Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR). *Br J Haematol.* 2023 Jul;202(1):40-47
- 26 Sahinbegovic H, Vdovin A, Snaurova R, Durech M, Nezval J, Sobotka J, Hajek R, Jelinek T, Simicek M. Length-Dependent Translation Efficiency of ER-Destined Proteins. *Curr Issues Mol Biol.* 2023 Aug 14;45(8):6717-6727
- 27 Lebedzik M, Turečkova K, Majerova I, Nevima J, Hradská K, Popková T, Skořupová M, Hájek R. An economic evaluation of the effectiveness of telemedicine in hematooncology. *PLoS One.* 2023 Nov 14;18(11):e0291143.
- 28 van de Donk NWCJ, Minnema MC, van der Holt B, Schjesvold F, Wu KL, Broijl A, Roeloffzen WWH, Gadisseur A, Pietrantuono G, Pour L, van der Velden VHJ, Lund T, Offidani M, Grasso M, Giaccone L, Razawy W, Tacchetti P, Mancuso K, Silkjaer T, Caers J, Zweegman S, Hájek R, Benjamin R, Vangsted AJ, Boccadoro M, Gay F, Sonneveld P, Musto P. Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study. *Lancet Oncol.* 2023 Oct;24(10):1119-1133.
- 29 Kateřina Ryšánková, Jaromír Gumulec, Michal Grepl, Jan Krhut. Acquired haemophilia as a complicating factor in treatment of non-muscle invasive bladder cancer: A case report. *World J Clin Cases.* 2023 Aug 6;11(22):5338-5343.
- 30 Ingrid Skornova, Tomas Simurda, Lucia Stanciakova, Viliam Lauko, Pavol Holly, Matej Samos, Tomas Bolek, Martin Schnierer, Miroslava Drotarova, Kristina Maria Belakova, Juraj Sokol, Jan Stasko, Marian Mokban, Jaroslav Gumulec, Leona Chrastinova. A Functional Assay for the Determination of Heparin-Induced Thrombocytopenia via Flow Cytometry. *Diagnostics (Basel).* 2023 Sep 21;13(18):3019.
- 31 Rossi G, Salmanton-García J, Cattaneo C, Marchesi F, Dávila-Valls J, Martín-Pérez S, Itri F, López-García A, Glenthøj A, Gomes da Silva M, Besson C, Marchetti M, Weinbergerová B, Jaksic O, Jiménez M, Bilgin YM, Van Doesum J, Farina F, Žák P, Verga L, Collins GP, Bonuomo V, Van Praet J, Nucci M, Meers S, Espigado I, Fracchiolla NS, Valković T, Poulsen CB, Čolović N, Dragonetti G, Ledoux MP, Tascini C, Buquicchio C, Blennow O, Passamonti F, Machado M, Labrador J, Duarte RF, Schönlein M, Prezioso L, Falces-Romero I, Kulasekararaj A, Garcia-Vidal C, Fernández N, Abu-Zeinah G, Ormazabal-Vélez I, Adžić-Vukičević T, Piukovics K, Stoma I, Cuccaro A, Magliano G, Sztokowski T, González-López TJ, El-Ashwah S, Bergantim R, Sili U, Maertens J, Demirhan F, De Ramón C, Petzer V, Del Principe MI, Navrátil M, Dargenio M, Seval GC, Samarkos M, Ráčil Z, Pinczés LI, Lahmer T, Busca A, Méndez GA, Vena A, Biernat MM, Merelli M, Calbacho M, Barac A, Bavastro M, Limongelli A, Ilhan O, Wolf D, Çolak GM, García-Sanz R, Emarah Z, Mišković B, Gräfe SK, Mladenović M, Aiello TF, Núñez-Martín-Buitrago L, Nordlander A, Arellano E, Zambrotta GPM, Ammatuna E, Cabirta A, Sacchi MV, Nunes Rodrigues R, Hersby DS, Hanakova M, Rahimli L, Cordoba R, Cornely OA, Pagano L. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings. *Int J Infect Dis.* 2023 Oct 18;137:98-110
- 32 Viera Sandecka, Tereza Popkova, Martin Stork, Vladimir Maisnar, Jiri Minarik, Alexandra Jungova, Petr Pavlicek, Lukas Stejskal, Lenka Pospisilova, Adriana Heindorfer, Jarmila Obernauerova, Evzen Gregora, Michal Sykora, Jana Ullrychova, Marek Wrobel, Petr Kessler, Tomas Jelinek, Peter Kunovszki, Sacheeta Bathija, Blanca Gros, Sabine Wilbertz, Qian Cai, Annette Lam, Ivan Spicka. Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies. *Blood Cancer J.* 2023 Sep 27;13(1):153.
- 33 Valeria Skopelidou, Pavel Hurník, Lubomír Tulinský, Vladimír Židlík, Jiří Lenz, Patricie Delongová, Helena Hornychová, Patrik Flodr, Tomáš Jelínek, Ludmila Muroňová, Dušan Holub, Petr Džubák, Marián Hajdúch. A unique case of AH-dominant type nodular pulmonary amyloidosis presenting as a spontaneous pneumothorax: a case report and review of the literature. *Pathol Oncol Res.* 2023 Sep 22;29:1611390.
- 34 MOTAIS, B.; CHARVÁTOVÁ, S.; WALEK, Z.; HÁJEK, R.; BAGÓ, J.R. NK92 Expressing Anti-BCMA CAR and Secreted TRAIL for the Treatment of Multiple Myeloma: Preliminary In Vitro Assessment. *Cells* 2023;12:2748.

- 35 Hamadani M, Coleman M, Boccia R, Duras J, Hutchings M, Zinzani PL, Cordoba R, Oreiro MB, Williams V, Liu H, Stouffs M, Langmuir P, Sancho JM. Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study. *Hematol Oncol*. 2023 Dec;41(5):848-857.
- 36 Ivo Demel, David Skopal, Eliška Šafránková, Petra Rozsivalová, Pavel Jindra, Jiří Šrámek, Adéla Turková, Jan Vydra, Klára Labská, Jana Vedrová, Martin Čerňan, Tomáš Sztokowski, Heidi Móciková, Lenka Hynková, Ondřej Šušol, Ingrid Kováčová, David Belada, Roman Hájek. Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study. *Ann Hematol*. 2024 Mar;103(3):981-992.
- 37 Musto P, Salmanton-García J, Sgherza N, Bergantim R, Farina F, Glenthøj A, Cengiz Seval G, Weinbergerová B, Bonuomo V, Bilgin YM, van Doesum J, Jaksic O, Víšek B, Falces-Romero I, Marchetti M, Dávila-Valls J, Martín-Pérez S, Nucci M, López-García A, Itri F, Buquicchio C, Verga L, Piukovics K, Navrátil M, Collins GP, Jiménez M, Fracchiolla NS, Labrador J, Prezioso L, Rossi E, Čolović N, Meers S, Kulasekararaj A, Cuccaro A, Blennow O, Valković T, Sili U, Ledoux MP, Batinić J, Passamonti F, Machado M, Duarte RF, Poulsen CB, Méndez GA, Espigado I, Demirkan F, Čerňan M, Cattaneo C, Petzer V, Magliano G, Garcia-Vidal C, El-Ashwah S, Gomes-Da-Silva M, Vena A, Ormazabal-Vélez I, van Praet J, Dargenio M, De-Ramón C, Del Principe MI, Marques-De-Almeida J, Wolf D, Sztokowski T, Obr A, Çolak GM, Nordlander A, Izuzquiza M, Cabirta A, Zambrotta GPM, Cordoba R, Žák P, Ammatuna E, Mayer J, Ilhan O, García-Sanz R, Quattrone M, Arellano E, Nunes-Rodrigues R, Emarah Z, Aiello TF, Hanakova M, Ráčil Z, Bavastro M, Limongelli A, Rahimli L, Marchesi F, Cornely OA, Pagano L. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the epicovideha registry. *Hematol Oncol*. 2024 Jan;42(1):e3240.
- 38 Ondřej Venglar, Veronika Kapustova, Anjana Anilkumar Sithara, David Zihala, Ludmila Muronova, Tereza Sevcikova, Jan Vrana, Alexander Vdovin, Jakub Radocha, Petra Krhovska, Matous Hrdinka, Michal Turjap, Tereza Popkova, Zuzana Chyra, Lucie Broskevicova, Michal Simicek, Zdenek Koristek, Roman Hajek, Tomas Jelinek. Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy. *Br J Haematol*. 2023 Oct 9. doi: 10.1111/bjh.19141. Online ahead of print.

## Články v recenzovaných a ostatních časopisech

- 1 Navrátil M, Defibrotid v léčbě syndromu obstrukce sinusoid/venookluzivní nemoci jater – přehled a kazuistika, *Onkologie*. 2023;17(Suppl. B), 11-16
- 2 Hájek R, Maisnar V, Minařík J, et al. Diagnostika a léčba mnohočetného myelomu - Doporučení České myelomové skupiny a Myelomové sekce České hematologické společnosti pro diagnostiku a léčbu mnohočetného myelomu. *Transfuzie Hematol Dnes* 2023; 29(Suppl 2): 2S1-2S142.
- 3 Havel M, Jelínek T, Pour L, Štork M, Minařík J, Jungová A, Špička I, Pavlíček P, Radocha J, Maisnar V, Wróbel M, Sýkora M, Ullrychová J, Muroňová L, Krčálová E, Buriánková E, Henzlová L, Havlová G, Zogala D, Hájek R. Standardizace 18F-FDG PET/CT u pacientů s mnohočetným myelomem: Společné doporučení České myelomové skupiny a České společnosti nukleární medicíny. *NuklMed* 2023;12:22-26
- 4 Havel M, Jelínek T, Pour L, Štork M, Minařík J, Jungová A, Špička I, Pavlíček P, Radocha J, Maisnar V, Wróbel M, Sýkora M, Ullrychová J, Muroňová L, Krčálová E, Buriánková E, Henzlová L, Havlová G, Zogala D, Hájek R. Standardizace PET/CT u pacientů s mnohočetným myelomem – Společné doporučení České myelomové skupiny a České společnosti nukleární medicíny. *Transfuzie Hematol Dnes* 2023; 29(1): 1– 5
- 5 Gumulec, J. et al., Doporučený postup stratifikace rizika trombózy a cílené trombopropylaxe u žen podstupujících asistovanou reprodukci. *Transfuzie Hematol. dnes* 2023;29(1):51-59.
- 6 P. Tesařová; D. Karetová; J. Hirmerová; R. Malý; S. Vokurka; T. Kvasnička; P. Kessler; P. Ďulíček; J. Gumulec; V. Maňásek; J. Cvek; J. Prausová; B. Melichar; J. Kopecký; J. Kleinová; P. Aulický; J. Blatný; M. Penka. Prevence, diagnostika a léčba trombózy spojené se zhoubným nádorem. *Transfuzie Hematol. dnes* 2023;29(1): 61-67.
- 7 T. Kozák; J. Čermák; O. Černá; L. Červinek; J. Gumulec; A. Hluší; E. Konířová; M. Košťál; J. Maaloufová; D. Pospíšilová; P. Smíšek. Doporučení České hematologické společnosti pro diagnostiku a léčbu imunitní trombocytopenie dospělých. *Transfuzie Hematol. Dnes* 2023;29(1):68-77.
- 8 Zuchická J. Léčba opakovaně relabující chronické lymfocytární leukemie akalabrutinibem. *Farmakoterapie* 2023;19(supplementum 6):1–28
- 9 Navrátil M., Primární profylaxe letermovirem CMV reaktivace/infekce u pacientů po alogenní transplantaci krvetorby – přehled současných znalostí a příklad použití – kazuistika, *Onkologická revue*, 2023,10(6):501-504.
- 10 Jozef Michalka, Zdeněk Král, Jana Marková, Ľubica Gahérová, Mária Maco, Vít Procházka, Andrea Janíková, Jan Kořen, Alice Sýkorová, Pavla Štěpánková, Kateřina Steinerová, Lekaa Mohammad, Juraj Ďuraš, et al. Konsolidační léčba brentuximab vedotinem u pacientů s relabujícím/refrakterním klasickým Hodgkinovým lymfomem po provedení autologní transplantace hematopoetických kmenových buněk v České republice. *Onkologie*, 2023, 17.4: 267-272.

## Kapitoly v knihách

- 1 Jelínek T, Hájek R. Mnohočetný myelom in Tomáš Büchler a kol. Klinická onkologie. 978-80-7345-758-7
- 2 Kořístek Z, Jelínek T, Hájek R. Vysokodávkovaná chemoterapie s transplantací krvetvorných buněk in Tomáš Büchler a kol. Klinická onkologie. 978-80-7345-758-7

## Postery (výběr):

- 1 K. Hradská, M. Pulcer, M. Skořupová, V. Kelbichová, V. Hanzelková, T. Popková, M. Augustynek, R. Hájek. Evaluace point-of-care analyzátoru HemoScreen pro měření nestandardních krevních obrazů. Pařížkovy dny, Ostrava 3/2023
- 2 Kuter, D.J.J., Gumulec J. et al., Long-Term Efficacy and Safety With Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients With Immune Thrombocytopenia. ISTH Congress 2023
- 3 Jelínek T., Zihala D., Sevcikova T., Anilkumar Sithara A., Kapustova V., Sahinbegovic H., Venglar O., Muronova L., Broskevicova L., Bilek D., Popkova T., Plonkova H., Vrana J., Zidlik V., Hurnik P., Havel M., Hrdinka M., Chyra Z., Stracquadanio G., Simicek M., Hajek R. Multiomics profiling of extramedullary multiple myeloma tumors and their microenvironment. IMS 2023, Athens
- 4 Jelínek Tomas, Muronova Ludmila, Zihala David, Sevcikova Tereza, Popkova Tereza, Plonkova Hana, Venglar Ondrej, Pour Ludek, Stork Martin, Rihova Lucie, Bezdekova Renata, Minarik Jiri, Novak Martin, Jungova Alexandra, Chena David, Straub Jan, Spacek Martin, Rezacova Vladimira, Soucek Ondrej, Maisnar Vladimir, Radocha Jakub, Roman Hajek P-075 Real-world evidence on prognostic value of minimal residual disease in multiple myeloma: Czech experience. Clinical Lymphoma, Myeloma and Leukemia 2023; 23: S75–S76., IMS 2023, Athens
- 5 Jelínek T, Spencer A, Krishnan A, Trudel S, Harrison S, Breuleux M et al. Novel combination immunotherapy for relapsed/refractory multiple myeloma (RRMM): initial Phase 1 safety run-in results for cevostamab in combination with pomalidomide and dexamethasone. Clinical Lymphoma, Myeloma and Leukemia 2023; 23: S43. IMS 2023, Athens
- 6 Popková T, Pour L, Spicka I, Radocha J, Jungova A, Minarik J et al. REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS. HemaSphere 2023; 7: e0151603. EHA 2023, Frankfurt
- 7 Radocha J, Jungova A, Pour L, Špička I, Minarik J, Jelínek T et al. Lenalidomide maintenance in R2-ISS stratified multiple myeloma patients-real world evidence. Clinical Lymphoma, Myeloma and Leukemia 2023; 23: S122–S123. IMS 2023, Athens
- 8 Radocha J, Pour L, Jelínek T, Minarik J, Jungova A, Novakova D et al. Early infections in myeloma patients treated with anti-BCMA bispecific antibodies. Clinical Lymphoma, Myeloma and Leukemia 2023; 23: S57–S58. IMS 2023, Athens
- 9 Spicka I, Lapidot I, Merz M, Radocha J, Stork M, Jelínek T et al. REAL-WORLD PATIENT CHARACTERISTICS AND SURVIVAL OUTCOMES OF LENALIDOMIDE REFRACTORY VS. LENALIDOMIDE EXPOSED RRMM PATIENTS IN THE HONEUR FEDERATED DATA NETWORK. HemaSphere 2023; 7: e258126d. EHA 2023, Frankfurt
- 10 Turi M, Sithara AA, Hofmanová L, Žihala D, Radhakrishnan D, Vdovin A et al. PB2397: TRANSCRIPTOME ANALYSIS OF DIFFUSE LARGE B-CELL LYMPHOMA CELLS EXPRESSING MYD88 L265P REVEALS CD44, LGALS3, NFKB1 AND BATF AS DOWNSTREAM TARGETS OF ONCOGENIC NF-KB SIGNALING. HemaSphere 2023; 7: e4265786. EHA 2023, Frankfurt
- 11 David Zihala, Tomas Jelínek, Tereza Sevcikova, Anjana Anilkumar Sithara, Veronika Kapustova, Daniel Bilek, Hana Sahinbegovic, Tereza Popkova, Hana Plonkova, Lucie Broskevicova, Ondrej Venglar, Jan Vrana, Vladimir Zidlik, Martin Havel, Zdenek Koristek, Matous Hrdinka, Zuzana Chyra, Michal Simicek, and Roman Hajek. EXTRAMEDULLARY MULTIPLE MYELOMA: MOLECULAR PATHOGENESIS AND NOVEL THERAPEUTIC TARGETS. HemaSphere 2023; 7: e003730a. EHA 2023, Frankfurt
- 12 Zabaleta A. Jelínek T. et al. A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent for the Treatment of Older Patients with Acute Myeloid Leukemia (AML). ASH, 2023
- 13 Minarik J., Jelínek T., et al. Comparison of Lenalidomide Based Triplets (IRD, KRd and DRd) in Relapsed and Refractory Multiple Myeloma in Routine Practice. ASH, 2023
- 14 Plonková H., Popková T., Jelínek T., Muroňová L., Szeligová L., Janušková M., Svatošová J., Merendová K., Hájek R. Výsledky léčby pacientů s mnohočetným myelomem na Klinice hematooonkologie FNO v letech 2013-2022. XXIX. Pařížkovy dny, 15.-17.3.2023
- 15 Plonková H., Popková T., Jelínek T., Muroňová L., Szeligová L., Kusalová E, Hájek R. Výsledky sledování pacientů s monoklonální gamapatií nejistého významu za deset let Kliniky hematooonkologie FNO. XXIX. Pařížkovy dny, 15.-17.3.2023

- 16 Dhvani Radhakrishnan, Marcello Turi, Matous Hrdinka. Unraveling the Role of Deubiquitinases in Blood Cancer Biology: A Comprehensive CRISPR-Cas9 Approach, EWCD 6/2023
- 17 Marcello Turi, Jana Kotulova, Dhvani Radhakrishnan, Sofija Knapkova, Lucie Hofmanova, Roman Hajek, Matous Hrdinka. Deubiquitinases USP5 and USP13 as Novel Targets for MyD88-Mediated Lymphomagenesis. EWCD 6/2023
- 18 K. Hradská, M. Pulcer, M. Skořupová, V. Kelbichová, V. Hanzelková, T. Popková, M. Augustynek, R. Hájek: Evaluate point-of-care analyzátoru HemoScreen pro měření nestandardních krevních obrazů. Pařížkovy dny 2023